Online Education
- Home
- Online Education
Important Note
You will need to login first in order to enroll or view an activity. Login Here
*Note: ✔ = Contact Hours Provided AND ✖ = No Contact Hours Provided
Comprehensive Care of Adolescents and Young Adults with Sickle Cell Disease
- Credits: 1 (ACCME),1.0 (ANCC), 1 (AAPA)
- Expiration Date: July 8, 2022
Comprehensive Care of Adolescents and Young Adults with Sickle Cell Disease Details
Activity Number and Title
21HT50948 - Comprehensive Care of Adolescents and Young Adults with Sickle Cell Disease
Release Date
July 8, 2021
Expiration Date
5:00 PM Eastern, July 8, 2022
The estimated time to complete this activity is 60 minutes.
Purpose Statement
The purpose of this activity is to enable the learner to gain knowledge necessary to better manage the comprehensive care of adolescents and young adults with sickle cell disease, with the aim of improving health outcomes among these individuals.
Activity Description
This online educational activity covers screening tests that are important in the care of adolescent and young adults (AYAs) with sickle cell disease and the most commonly used medications in this patient group. It also covers reproductive health considerations of AYAs with sickle cell disease, including the need for contraception, the existing knowledge gaps, and the epidemiology and management of priapism. Finally, the activity addresses practical pain management strategies in AYAs with sickle cell disease.
Target Audience
This enduring material is intended for physicians, physician assistants, nurses, nurse practitioners, and other health care providers who treat persons with sickle cell disease (SCD) and wish to improve comprehensive care services provided to adolescents and young adults (AYAs) with sickle cell disease.
Educational Objectives
At the conclusion of this enduring material, the participants should be better able to:
- Interpret the screening tests needed for adolescents and young adults (AYAs) with sickle cell disease (SCD)
- Review common complications of SCD in AYAs with this condition
- Describe the contraceptive choices in girls and women with SCD
- Review management of priapism, both ischemic and stuttering, in males with SCD
- Discuss practical strategies in pain management for AYAs with SCD
- Identify disease-modifying therapies that are FDA-approved for the treatment of SCD
- Describe the primary gap in knowledge of reproductive issues for patients with SCD receiving hydroxyurea therapy
Faculty
- Emily Riehm Meier, MD, MSHS
Requirements for Successful Completion
In order to receive continuing education credits, you must complete these steps prior to the activity expiration date.
- Read the Disclosure Information found in the To Dos section.
- Complete the learning activity
- Complete the evaluation
- Complete the post-test with a score of 70% or better
- Upon successful completion of the post-test your certificate of completion will be available to print or save
Accreditation Statement and Contact Hours
In support of improving patient care, this activity has been planned and implemented by University of Nebraska Medical Center and Indiana Hemophilia & Thrombosis Center. University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
The University of Nebraska Medical Center designates this enduring material for a maximum of 1 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The University of Nebraska Medical Center designates this activity for 1.0 ANCC contact hour. This activity is provided for 0.25 contact hours related to pharmacotherapeutic content. Nurses should only claim credit for the actual time spent participating in the activity.
This activity has been reviewed by the AAPA Review Panel and is compliant with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid from 5/27/2021 to 5/26/2022. PAs should only claim credit commensurate with the extent of their participation. AAPA reference number: CME-202575.
Financial Support
No commercial support was received for this activity.
Contact Information
If you have any questions about this activity, please contact Brooke Hernandez in Indianapolis, IN, 317-871-0011 ext. 813 or via email at bhernandez@ihtc.org. For technical support please email support@partnersprn.org or open a ticket in the Partners Support Center.
System Requirements
- 2 gigabytes of RAM
- High-speed internet connection
- Internet browser (current version) Firefox, Safari, Chrome, or Explorer
- Cookies and JavaScript must be enabled in the browser
Hydroxyurea for the Treatment of Sickle Cell Disease
- Credits: 0.75 (ACCME), 0.75 (ANCC), 0.75 (AAPA)
- Expiration Date: July 8, 2022
Hydroxyurea for the Treatment of Sickle Cell Disease Details
Activity Number and Title
21HT50949 - Hydroxyurea for the Treatment of Sickle Cell Disease
Release Date
July 9, 2021
Expiration Date
5:00 PM Eastern, July 8, 2022
The estimated time to complete this activity is 45 minutes.
Purpose Statement
The purpose of this activity is to enable learners to enhance his or her knowledge about the complications of sickle cell disease and the importance of hydroxyurea in reducing or preventing those complications; as well as to gain familiarity with the 2014 NHLBI guidelines concerning hydroxyurea treatment for adults living with sickle cell disease.
Activity Description
This online educational activity reviews the most common complications of sickle cell disease and introduces the most efficacious therapy currently available to treat and prevent these complications, hydroxyurea. The author discusses the rational behind hydroxyurea as a therapy, its effectiveness, and national prescribing guidelines.
Target Audience
This enduring material is intended for physicians, physician assistants, nurses, nurse practitioners, and other health care providers who treat persons with sickle cell disease and wish to improve their knowledge of hydroxyurea as a treatment for sickle cell disease as well as hydroxyurea prescribing practices, with the aim of improving health outcomes among persons with sickle cell disease.
Educational Objectives
At the conclusion of this enduring material, the participants should be better able to:
- Describe the most common complications of sickle cell disease, including acute chest syndrome, vaso-occlusive pain crisis, and stroke
- Discuss the rationale behind hydroxyurea as a treatment for sickle cell disease and its effectiveness at preventing sickle cell-related complications
- Analyze the mechanism of action, dosing, side effects, contraindications, and monitoring of hydroxyurea therapy for sickle cell disease
- Review the 2014 NHLBI Guidelines for hydroxyurea treatment for persons living with sickle cell disease
Faculty
- Emily Riehm Meier, MD, MSHS
Requirements for Successful Completion
In order to receive continuing education credits, you must complete these steps prior to the activity expiration date.
- Read the Disclosure Information found in the To Dos section.
- Complete the learning activity
- Complete the evaluation
- Complete the post-test with a score of 70% or better
- Upon successful completion of the post-test your certificate of completion will be available to print or save
Accreditation Statement and Contact Hours
In support of improving patient care, this activity has been planned and implemented by University of Nebraska Medical Center and Indiana Hemophilia & Thrombosis Center. University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
The University of Nebraska Medical Center designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The University of Nebraska Medical Center designates this activity for 0.75 ANCC contact hours. This activity is provided for 0.3 contact hours related to pharmacotherapeutic content. Nurses should only claim credit for the actual time spent participating in the activity.
This activity has been reviewed by the AAPA Review Panel and is compliant with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credits. Approval is valid from 5/1/2021 to 5/2/2022. PAs should only claim credit commensurate with the extent of their participation. AAPA reference number: CME-202570.
Financial Support
No commercial support was received for this activity.
Contact Information
If you have any questions about this activity, please contact Brooke Hernandez in Indianapolis, IN, 317-871-0011 ext. 813 or via email at bhernandez@ihtc.org. For technical support please email support@partnersprn.org or open a ticket in the Partners Support Center.
System Requirements
- 2 gigabytes of RAM
- High-speed internet connection
- Internet browser (current version) Firefox, Safari, Chrome, or Explorer
- Cookies and JavaScript must be enabled in the browser
Understanding Hemophilia
- Credits: 2.0 (ANCC), 2.00 (AAPA)
- Expiration Date: February 23, 2024
Understanding Hemophilia Details
Activity Number and Title
22HT00046 Understanding Hemophilia
Release Date
February 24, 2022
Expiration Date
5:00 PM Eastern, February 23, 2024
The estimated time to complete this activity is 120 minutes.
Purpose Statement
"Understanding Hemophilia" is a 6-part online learning activity that aims to enable clinicians at U.S. Hemophilia Treatment Centers to gain knowledge and develop expertise on the pathogenesis, inheritance, symptoms, potential complications, and clinical management of hemophilia.
Activity Description
This 6-part online learning activity introduces basic concepts of hemophilia.
Part 1: Pathogenesis & Inheritance examines the coagulation system and processes, the deficit in hemophilia that interferes with clot formation, differences among types of hemophilia, and the sex-linked inheritance pattern of hemophilia.
Part 2: Symptoms & Sequelae distinguishes bleeding patterns and clinical presentation of hemophilia based on severity, differentiates types of bleeding episodes, and discusses physical/psychosocial sequelae of hemophilia.
Part 3: Factor Concentrates & Hemophilia Management discusses episodic and prophylactic management of hemophilia with clotting factor concentrate, different factor therapy protocols, and nursing considerations in administration of clotting factor concentrates.
Part 4: Introduction to Inhibitors explains the immune response and inhibitor development, signs/symptoms and risk factors of inhibitors, the impact of inhibitors on persons with hemophilia, inhibitor treatment strategies and challenges, and the positive health outcomes of immune tolerance induction therapy.
Part 5: Emicizumab covers the novel agent emicizumab, including its indications, mechanism of action, dosing options, lab considerations; as well as management of breakthrough bleeding, the boxed warning of emicizumab, use of emicizumab concurrently with bypassing agents, and potential considerations in the management of persons with hemophilia with or without inhibitors who utilize emicizumab.
Part 6: Carrier Considerations reviews hemophilia sex-linked genetics and introduces recommendations for the management of carriers and women with hemophilia, neonatal diagnosis and circumcision in males with hemophilia, and key considerations of postpartum management of carriers and women with hemophilia.
Target Audience
This enduring material is intended for nurses, nurse practitioners, physician assistants, and other clinical staff within the federally recognized U.S. Hemophilia Treatment Center (HTC) network who wish to develop an understanding of basic concepts of hemophilia. The activity is particularly appropriate for clinicians within their first six months of employment at an HTC.
Educational Objectives
At the conclusion of this enduring material, the participants should be better able to:
- Describe the pathogenesis and inheritance patterns concerning the different factor deficiencies in hemophilia including the symptoms and sequelae that may occur
- Discuss the target factor levels for situational bleeding episodes in conjunction with the appropriate factor replacement protocols, prophylactic treatments, and nursing considerations in administration of clotting factor concentrates
- Review the development and impact of inhibitors on persons with hemophilia, including signs and symptoms, risk factors, treatment implications, and nursing considerations
- Summarize the MASAC recommendations on the use of Emicizumab such as the indications, management approaches, and concurrent use with bypassing agents
- Articulate the role of genetic testing in the identification of potential carriers and women with hemophilia and the hemostatic management recommendations during pregnancy, labor and delivery, and the postpartum phases
Faculty w/ credentials
- Jennifer Maahs, MSN, PNP, RN-BC
- Amy Shapiro, MD
Requirements for Successful Completion
In order to receive continuing education credits, you must complete these steps prior to the activity expiration date
- Read the Disclosure Information found in the To Dos section.
- Complete the learning activity
- Complete the evaluation
- Complete the post-test with a score of 80% or better.
- Upon successful completion of the post-test your certificate of completion will be available to print or save
Accreditation Statement and Contact Hours
In support of improving patient care, this activity has been planned and implemented by University of Nebraska Medical Center and Partners in Bleeding Disorders Education Program. University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
NURSES/NURSE PRACTITIONERS
The University of Nebraska Medical Center designates this activity for 2.0 ANCC contact hour(s). This activity is provided for 0.3 contact hours related to pharmacotherapeutic content. Nurses should only claim credit for the actual time spent participating in the activity.
PHYSICIAN ASSISTANTS
University of Nebraska Medical Center has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 2 AAPA Category 1 CME credits. Approval is valid until February 23, 2024. PAs should only claim credit commensurate with the extent of their participation.
Financial Support
Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.
Contact Information
If you have any questions about this activity, please contact Brooke Hernandez in Indianapolis, IN, 317-871-0011 ext. 813 or via email at bhernandez@ihtc.org. For technical support please email support@partnersprn.org or open a ticket in the Partners Support Center.
System Requirements
- 2 gigabytes of RAM
- High-speed internet connection
- Internet browser (current version) Firefox, Safari, Chrome, or Explorer
- Cookies and JavaScript must be enabled in the browser
The Partners in Bleeding Disorders Education Program is supported by educational grants from Takeda Pharmaceuticals U.S.A, Inc.; Genentech, a member of the Roche Group; and the National Hemophilia Foundation (NHF).
Copyright © 2022 Indiana Hemophilia & Thrombosis Center. All rights reserved. Privacy Policy | Travel Policy | Terms of Service Credits